2.3. Procedures
thirst, gastrointestinal tolerance, overdose, hypoglycemia, weight loss
HYPOGLYCEMIA, CONCOMITANT DISEASE
In order to improve gastrointestinal tolerance, all patients in the group received a weekly dose titration. The initial dose of the test group was once a day, 500 mg metformin and 15 mg pioglitazone (both from Hangzhou Zhongmei Huadong Pharma Ceutical Co., Ltd.) were taken before breakfast or dinner, and after 1 week of treatment, the dose was adjusted to twice a day, before breakfast and dinner. The initial dose of the control group was 500 mg metformin, once a day, before breakfast or dinner, and after 1 week of treatment, the dose was adjusted to twice a day, before breakfast and dinner. Patients were visited at 2, 4, 8, 12, 16, 20, and 24 weekends after treatment to evaluate the effectiveness and safety of the trial drug.Participants will withdraw from the experiment when the following situations occur: severe hypoglycemia requires the assistance of others; fasting blood glucose < 2.8 mmol/L or two random blood glucose < 3.9 mmol/L caused by overdose; in the absence of other concomitant diseases, frequent urination, thirst, weight loss, or other aggravation due to high blood sugar; and asymptomatic FPG confirmed by two measurements > 13.3 mmol/L.